hit counter

Nanotechnology For Depression: The Futuristic Potential of Nanopsychiatry

Most pharmacological-based treatments for depression aim to increase levels of various neurotransmitters, particularly serotonin (5-HT).  It is thought that approximately 2 out of 3 individuals that seek treatment with standard antidepressants such as SSRIs and SNRIs are able to attain therapeutic relief.  For a certain percentage of these individuals, the benefits of using pharmaceutical interventions …

Read more

Invega (Paliperidone) Withdrawal Symptoms: List of Possibilities

Invega (Paliperidone) is an atypical antipsychotic approved in 2006 for the treatment of schizophrenia.  Several years later in 2009, a longer-acting format of the medication called “Invega Sustenna” was also approved.  Invega Sustenna is an injectable form of the drug that is administered every 4 weeks and is thought to be advantageous it mitigates risk …

Read more

Gene Therapy For Depression: A Futuristic Treatment

Despite the fact that pharmaceutical companies continue to promote the concept of “chemical imbalances” as the root cause of depression, this is a vast oversimplification of an infinitely more complex condition.  While a chemical imbalance may be one of the primary contributing factors to a person’s depression, what causes the chemicals (neurotransmitters) to become imbalanced …

Read more

RNAi For Depression: siRNA Targets SERT & 5-HT1A for Antidepressant Effect

It seems as though society is on the verge of ushering in a new generation of treatment modalities for depression and other psychiatric conditions.  While most people turn to pharmaceutical drugs for major depressive disorder, approximately 1 out of 3 people fail to get sufficient symptomatic relief.  To make matters worse, many end up trying …

Read more

Rexulti (Brexpiprazole) Approved For Schizophrenia & Depression (Adjunct)

Rexulti (Brexpiprazole) is a drug that was approved July 10, 2015 for the treatment of schizophrenia and as an adjunctive option for major depressive disorder.  In clinical trials it was referred to as the chemical “OPC-34712” and is being marketed as a superior successor to Abilify (Aripiprazole) due to the fact that Abilify’s patent expired …

Read more